Skip to content

Hepatitis C

EASL 2020 ("final update of the series") and the AASLD/IDSA 2023 guidance update agree: treat everyone with a pangenotypic DAA.

EASL 2020

International Current

EASL recommendations on treatment of hepatitis C: Final update of the series

Official source

AASLD-IDSA 2023

International Current

Hepatitis C Guidance 2023 Update: AASLD–IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

Official source

Clinical pearls

  • Diagnosis: anti-HCV antibody, then HCV RNA to confirm active infection.
  • Glecaprevir/pibrentasvir 8 weeks or sofosbuvir/velpatasvir 12 weeks, without genotyping.
  • Decompensated cirrhosis: sofosbuvir/velpatasvir + ribavirin 12 weeks; no protease inhibitors.
  • Cirrhosis after SVR: HCC surveillance continues for life.